Brief: FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation To AlloVir’s Posoleucel For The Treatment Of Adenovirus (AdV) Infections In Adults And Children Post-Allogeneic Stem Cell Transplantation

Kalaris Therapeutics

05/01/2022 12:44

Jan 5 (Reuters) - Allovir Inc  ALVR.O :
    * FDA GRANTS REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT)
DESIGNATION TO ALLOVIR’S POSOLEUCEL FOR THE TREATMENT OF
ADENOVIRUS (ADV) INFECTIONS IN ADULTS AND CHILDREN
POST-ALLOGENEIC STEM CELL TRANSPLANTATION
    * ALLOVIR INC - PHASE 3 REGISTRATIONAL STUDY OF POSOLEUCEL
FOR ADV
TREATMENT IS NOW OPEN FOR ENROLLMENT
    * ALLOVIR INC - PROOF-OF-CONCEPT STUDY OF ALVR106 FOR
TREATMENT OF
MULTIPLE RESPIRATORY VIRAL INFECTIONS IS ALSO OPEN FOR
ENROLLMENT
    * ALLOVIR INC - DESIGNATION IS BASED ON POSITIVE RESULTS
FROM
PHASE 2 CHARMS STUDY.

Source text for Eikon:  ID:nBw5gxdsLa 
Further company coverage:  ALVR.O 

 ((Reuters.Briefs@thomsonreuters.com;))